Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Fusen Pharmaceutical Co. Ltd. has announced the acceptance of their Phase II clinical trial application for SY617, an innovative traditional Chinese medicine aimed at treating influenza with promising prospects. SY617, which targets symptoms of wind-heat with dampness syndrome, strengthens the company’s anti-flu product line and offers a fresh treatment alternative amidst the RMB 8.5 billion traditional Chinese cold medicine market. This development could provide a significant boost to the company’s portfolio and offer patients more options for flu treatment.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.